Benzinga | May 5, 2021 04:41PM EDT

Adaptive Biotechnologies Q1 EPS $(0.29) Beats $(0.41) Estimate, Adj. EBITDA Loss $30.1M, Sales $38.40M Beat $27.75M Estimate; Sees FY21 Sales $145M-$155M vs $149.9M Est.

Adaptive Biotechnologies (NASDAQ:ADPT) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0.41) by 29.27 percent. This is a 16 percent decrease over losses of $(0.25) per share from the same period last year. The company reported quarterly sales of $38.40 million which beat the analyst consensus estimate of $27.75 million by 38.38 percent. This is a 83.64 percent increase over sales of $20.91 million the same period last year.